Clinical meaning
Preconception counseling is grounded in the understanding that organogenesis — the critical period of embryonic organ formation — occurs during weeks 3-8 of gestation, often before a woman knows she is pregnant. This narrow developmental window is when the embryo is most vulnerable to teratogenic insults, making preconception optimization essential rather than reactive prenatal adjustment. The neural tube closes by day 28 post-conception, which is why folic acid supplementation must begin at least one month before conception to achieve adequate tissue levels (≥400 mcg/day for low-risk women, 4 mg/day for women with prior NTD-affected pregnancy). Folic acid acts as a methyl donor essential for DNA synthesis and cellular proliferation during rapid embryonic development; deficiency impairs neural tube closure, resulting in anencephaly or spina bifida. Preconception glycemic control in diabetes is critical because hyperglycemia during organogenesis (HbA1c >6.5%) increases congenital anomaly risk 2-3 fold (cardiac septal defects, neural tube defects, caudal regression syndrome, sacral agenesis) through oxidative stress-mediated teratogenesis — reactive oxygen species generated by hyperglycemia disrupt expression of the PAX3 gene essential for neural crest cell migration and cardiac septation. Medication review addresses teratogenic risk by understanding critical drug mechanisms: valproic acid inhibits histone deacetylases (HDACs) essential for gene regulation during neural crest and neural tube development, causing neural tube defects in 1-2% of exposed pregnancies; ACE inhibitors and ARBs disrupt the fetal renin-angiotensin system essential for renal development, causing renal agenesis, oligohydramnios, and Potter sequence when used in the second and third trimesters; warfarin crosses the placenta and inhibits vitamin K-dependent proteins essential for fetal bone and cartilage formation, causing nasal hypoplasia and stippled epiphyses (warfarin embryopathy) during first-trimester exposure; isotretinoin disrupts retinoic acid signaling critical for craniofacial, cardiac, and thymic development. Pregnancy-related pharmacokinetic changes further complicate medication management: plasma volume expands 40-50% (diluting drug concentrations), GFR increases 50% (accelerating renal drug clearance), hepatic CYP3A4 activity increases while CYP1A2 decreases, and albumin levels fall (increasing free fractions of protein-bound drugs).